Every material Form 8-K MANGOCEUTICALS, INC. has filed with the SEC since August 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Mangoceuticals' sole Series B preferred holder approved terms for a new 8% Series D convertible cumulative preferred stock and an amendment to the Series B designation, which would allow the company to sell up to 1,000,000 shares at $10.00 each under Regulation A. The company said the instruments are not yet filed or effective and it may not proceed with the offering; the company also set its combined 2025 and 2026 annual meeting for December 30, 2026.
On November 2, 2026, the holder of all 50 outstanding Series B preferred shares approved the Series D terms and Series B amendment by written consent.
Proposed Series D offering: up to 1,000,000 shares at $10.00 per share under Regulation A; no sales will occur before the SEC qualifies the offering statement on Form 1-A.
Annual meeting set for December 30, 2026 in Dallas, Texas; record date is November 12, 2026.
Shareholder proposals and director nominations for the meeting are due by November 16, 2026.
Mangoceuticals sold 657,000 shares of common stock, each paired with a warrant, in a registered direct offering to certain investors, for gross proceeds of about $492,750, with closing on October 9, 2026. The unit price was a 74% premium to the referenced recent closing price of $0.43, but the warrants can add up to 788,400 shares and may dilute existing shareholders.
657,000 shares sold at $0.75 per share and accompanying warrant, for gross proceeds of about $492,750 before offering expenses
Warrants exercisable at $1.00 per share, immediately exercisable, expiring five years from issuance, covering up to 788,400 shares
Unit price represents an approximately 74% premium to the referenced recent closing share price of $0.43; no placement agent was engaged
Proceeds intended for working capital and general corporate purposes; separate $2.5 million MangoRx IP subsidiary investment does not involve parent-company shares
Mangoceuticals' subsidiary MangoRx IP Holdings, which holds the patent portfolio behind its MGX-0024 antiviral technology, entered into subscription agreements on September 30, 2026 with two accredited investors for a combined 25% membership interest at $2.5 million. The company received $1.75 million at the initial closing, and the remaining $750,000 is due by November 28, 2026. The company states that no Mangoceuticals common stock, warrants or other parent-company securities were issued, so the deal does not increase the parent's outstanding shares.
Two accredited investors agreed to buy a combined 25% membership interest in MangoRx IP for $2.5 million.
The company has received $1.75 million so far; the second payment of $750,000 is due by November 28, 2026.
No shares of Mangoceuticals common stock, warrants or other parent-company securities were issued, according to the company.
Proceeds are to fund commercialization of the MangoRx IP patent portfolio; the filing says the deal was made without a public offering.
Mangoceuticals and Nuclea Energy mutually agreed on August 19, 2026 to terminate their Business Combination Agreement, which had been dated July 29, 2026. The parties said the $15,000,000 PIPE financing minimum could not be raised by the August 21, 2026 outside date, so the financing closing condition could not be met on the agreed terms.
Termination agreed August 19, 2026 under Section 12.1(a) of the agreement, which was dated July 29, 2026
Closing required PIPE financing of at least $15,000,000 deposited into escrow; the outside date was August 21, 2026
Each party bears its own costs, and the parties exchanged mutual releases except for willful breaches before termination
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MANGOCEUTICALS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →